A detailed review of pharmacokinetics/pharmacodynamics of progestogens in oral contraception.

Front Endocrinol (Lausanne) · 2026 · PMC13061722 · PMID 41970977

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

These well-known generations showed a trend ( 1 ) to progressively decrease the EE content of COCs and potentially decreasing the thrombotic risk, and ( 2 ) to reduce androgenicity of progestogens for a better tolerability, the fourth generation even containing an anti-androgenic progestogen (DRSP).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.